Potential strategies to prevent encrustations on urinary stents and catheters – thinking outside the box: A European Network of Multidisciplinary Research to Improve Urinary Stents (ENIUS) Initiative


To link to this article: https://doi.org/10.1080/17434440.2021.1939010

Accepted author version posted online: 04 Jun 2021.
Potential strategies to prevent encrustations on urinary stents and catheters – thinking outside the box: A European Network of Multidisciplinary Research to Improve Urinary Stents (ENIUS) Initiative


1 Sorbonne Université, CNRS UMR 8234, Physico-chimie des Électrolytes et Nanosystèmes Interfaciaux, Paris, France
2 3B's Research Group, University of Minho, Barco Guimarães, Portugal
3 U-merge Research Office, London-Athens-Dubai
4 Dept. of Pharmaceutics, School of Pharmacy, University College London. UK
5 ARTORG Center for Biomedical Engineering Research, University of Bern, Switzerland
6 Dept. of Urology, University Medical Center Utrecht, Utrecht, The Netherlands
7 Jesus Uson Minimally Invasive Surgery Centre Foundation. Cáceres, Spain
8 Dept. of Urology, University Medical Center Rostock, Germany
9 LEPABE, Faculty of Engineering, University of Porto, Portugal
10 Organogenesis Laboratory, Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Finland
11 Flagship GeneCellNano, Infotech Oulu - Kvantum Institut, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Finland

All authors have contributed equally to this project

Corresponding authors:
Noor Buchholz (submitting author)  Ali Abou-Hassan
U-merge scientific office  Sorbonne Université
1, Menandrou Street  CRNS UMR 3234
Athens 14561  Physico-chimie des Électrolytes et Nanosystèmes Interfaciaux
Greece  Paris 75005
Email: scientific-Office@u-merge.com  ali.abou_hassan@sorbonne-universite.fr
noor.buchholz@gmail.com  France
Tel: +30 213045 5951
Running title: preventing urinary encrustations
Abstract

**Background:** Urinary stents have been around for the last 4 decades, urinary catheters even longer. They are associated with infections, encrustation, migration and patient discomfort. Research efforts to improve them have shifted onto molecular and cellular levels. ENIUS brought together translational scientists to improve urinary implants and reduce morbidity.

**Methods & materials:** A working group within the ENIUS network was tasked with assessing future research lines for the improvement of urinary implants. Topics were researched systematically using Embase and Pubmed databases. Clinicaltrials.gov was consulted for ongoing trials.

**Results:** Relevant topics were coatings with antibodies, enzymes, biomimetics, bioactive nano-coats, antisense molecules, and engineered tissue. Further, pH sensors, biodegradable metals, bactericidal bacteriophages, non-pathogenic uropathogens, enhanced ureteric peristalsis, electrical charges, and ultrasound to prevent stent encrustations were addressed.

**Conclusions:** All research lines addressed in this paper seem viable and promising. Some of them have been around for decades but have yet to proceed to clinical application (i.e. tissue engineering). Others are very recent and, at least in urology, still only conceptual (i.e. antisense molecules). Perhaps the most important learning point resulting from this pan-European multidisciplinary effort is that collaboration between all stakeholders is not only fruitful but truly essential.

**Keywords:** urinary stent, encrustation, biofilm, coating, material, biosensors, antibodies, biodegradable, bacteriophages, peristalsis, surface charge
Introduction

Urological stents and catheters are hollow tubes which maintain urinary drainage and manage obstructions [1]. They are used extensively in urology to provide a minimally invasive treatment for a wide range of indications including kidney stones, tumors, strictures and infection. They can also facilitate healing as a scaffold after injury or anastomosis, or be used as a prophylactic measure against stricture formation [2]. In modern urological practice, ureter stents and bladder catheters, and to a lesser extent urethral and prostate stents, have become indispensable tools. Over the course of time, many improvements on designs and constitutive materials have taken place in an attempt to improve their efficacy. Nevertheless, they remain associated with several adverse effects that limit their value as tools for long-term urinary drainage. Infection, encrustation, migration, hyperplastic urothelial reaction, and patient discomfort are the most common problems [3, 4]. Certain adverse effects can be alleviated to some extent by modifying materials and coatings [5], by changes in design [6, 7] and by adjusting the length and the position of the devices within the bladder [8]. However, such changes had so far elicited only limited effects.

Within the ENIUS network, a unique opportunity arose that scientists and clinicians from the whole of Europe and neighboring countries came together to discuss not only the state-of-the-art of urinary implant research, but also to provide a unique outlook on what is on the horizon in the field. The authors of this paper formed a working group tasked to look at novel and potential research approaches to improve urinary implants. As urinary stents and catheters share many similarities such as dwelling in a urinary environment, materials, flow designs, and propensity to biofilm formation and ensuing blockage, clinical and basic science research for both greatly overlap and are of relevance to each other, and consequently they have been addressed in this paper together. The first six paragraphs address novel approaches for coating catheters and stents to prevent biofilm formation, reduce friction, promote biocompatibility, and ameliorate patient tolerance. Such innovative approaches include antibody, enzyme, biomimetic, and bioactive nano-coatings, coating with antisense molecules, and coating with autologous engineered tissue. The next seven paragraphs focus on physico-chemical approaches such as pH-change sensors, biodegradable metals, use of bactericidal bacteriophages and non-pathogenic competitive uropathogens, and, especially
for the ureter, the use of enhanced ureteric peristalsis, electrical charges and ultrasound waves to prevent stent encrustations. The aim of this paper is not to present yet another review on device modifications already being produced and tested, but ideas and pilot researches into novel approaches on new levels such as nanoscale or molecular technologies. It also aims to give urologists and researchers an overview of recent developments in the fields of stent and catheter-related material science. It goes without saying that a paper like this cannot provide in-depth knowledge on each topic. The interested reader is therefore encouraged to make use of the extensive reference list for further reading.
Methods & materials

The European Network of Multidisciplinary Research to Improve Urinary Stents (ENIUS) is a collaborative project bringing together European stakeholders in the development of urinary stents such as bioengineers, chemists, material scientists, cell biologists, medical device companies, urologists and other interested parties to exchange expertise and to brainstorm towards improving urinary stents and reducing stent-associated morbidity. Within this framework, six working groups were tasked to assess the current state of the art in stents, computational simulation of fluid dynamics, evaluation of new stent designs, current biomaterials and coatings, and drug eluting stent technologies. The authors on this paper were tasked to assess future research lines to improve urinary stents [9]. Sub-topics were researched in a systematic literature search in the databases of Embase and Pubmed. Clinicaltrials.gov was consulted for ongoing trials. For further reading, an extensive reference list is attached.
Antibody coated stents

Historically, urology has been following cardiology in many aspects of stent and catheter technologies. Antibody-coated stents developed for cardiovascular stenting focus on the mitigation of stent re-stenosis by preventing intimal proliferation and promoting early stent endothelialisation. Antibodies on the stent surface target receptors of cells responsible for these processes effectively enhancing vascularization and preventing intimal hyperplasia and thrombosis [10-14]. In addition, the same stents can be designed as drug-eluting [12]. Although to our knowledge the concept of antibody coating has not yet been trialled in urology, antibodies on urinary stents and catheters could potentially capture molecules or cells that promote tissue regeneration for the repair of ureteral or urethral defects, and that provide a defensive barrier for urothelial hyperplasia and biofilm formation on polymeric and metallic stents. Firstly, components circulating in the urine that might fulfil those functions need to be identified. Then, antibodies need to be developed to bind these to the surface of the stents. Major considerations for future research are the differences between endothelium and urothelium, and between the biochemical environments in blood and urine.

Enzyme coated stents

Anti-microbial enzymes as active component of antimicrobial coatings have been utilized recently in the field of urinary catheters. These enzymes can act through various mechanisms: degrading structural components of microorganisms (hydrolytic enzymes), inducing production of antimicrobial substances in the living organism (oxidative enzymes), and preventing bacterial quorum sensing (quorum quenching enzymes) which ultimately prevent cell aggregation and production of virulent compounds [4].

In case of urinary catheters and stents, enzymes can be immobilized onto the surfaces either reversibly or irreversibly. Reversible immobilization includes methods through which the enzymes can be easily removed [15, 16]. However, irreversible methods are generally preferred because of the improved stability and lower extent of leaching [4]. Urological trials with antimicrobial enzyme coating are still in the early stages. It was demonstrated that in vitro a cellobiose dehydrogenase (CDH)/cellobiose stent coating inhibited several
urinary pathogens including MRSA by generating H$_2$O$_2$ thus demonstrating an ability to kill microbes on demand when biofilms were formed [17]. Also, stent coatings with oxalate-degrading enzymes were trialed in vitro [18] and in an animal study [19]. Encrustation often results from the deposition of calcium oxalate on the biomaterial surface. A commensal colonic bacterium Oxalobacter formigenes produces several oxalate-degrading enzymes, which, when used as a coat on silicone, resulted in an up to 53% reduction in encrustation with no apparent toxicity [18, 19].

Anti-microbial enzymes in urinary device coatings act therefore similarly to eluted antibiotics preventing infection and biofilm formation. Enzymes have advantages over antibiotics and other antimicrobial agents. Firstly, they are pathogen-specific, killing only specific pathogens and no other commensal bacteria. Secondly, bacterial resistance to enzymes is very rare. Antimicrobial enzymes are safer as they are natural, non-reactive and non-toxic to living organisms. However, compared to cheaper alternatives like silver and antibiotics, the production and purification of antimicrobial enzymes is expensive and they are proteins which can get denatured in extreme conditions (e.g. sterilization of device, storage and transport) [4].

**Biomimetic stents**

Again, cardiology research is leading the way when it comes to biomimetic stent surfaces. One would easily agree that nature’s creations usually outperform man-made solutions. Therefore, researchers try to mimic biological surfaces on stents to bring them as close to the “natural thing” as possible. Biomimetic approaches are tissue-engineering tactics aiming to design materials with physical and biological properties behaving physiologically like the urinary system itself [20].

In cardiology, stenting is currently the major therapeutic treatment. However, non-biogenic metal stents are inclined to trigger a cascade of cellular and molecular events leading to restenosis and thrombosis. To overcome these problems, an endothelium-mimicking stent coating was developed allowing a rapid regeneration of a completely functioning endothelial layer [21]. Another group synthetized a novel bioinspired phospholipid copolymer. Contact angle results indicated that the coating surface rearranged to get a more hydrophilic surface at the polymer/water interface. The biomimetic coating surface
resisted platelet adhesion and prolonged plasma re-calcification time significantly [22]. These are only two examples where biomimetic surfaces could create an ideal microenvironment to prevent re-stenosis. In addition, these surfaces can be used for drug elution as well [20].

In urology, experiments with catheter surfaces mimicking shark skin micro-patterns which have been shown to resist biofilm formation in nature [23] similarly inhibited colonization and migration of E. coli in vitro [24]. Although currently to our knowledge there are no ongoing trials in either, biomimetic stent composition or micro-patterns, this seems to be a promising technology. If it proves successful in cardiac stents, it will be consequently expanded to other medical devices including urinary stents and catheters.

**Bioactive nanocoating**

Immediately after introduction of any biomaterial into an organism, the adsorption of endogenous proteins on the surface starts with the subsequent attachment of cells controlled by this protein layer. Processes of cell recognition and signal transmission happen on a molecular level and can be altered by nanotechnological structure formation processes [25]. Nanoparticle sizes < 10-15 nm and irregular particle size distribution are regarded as critical for friction, roughness and surface dislocation [26].

The technologies for generating three-dimensional nanostructures include
- the application of a nanoscale coating to the original biomaterial surface and
- the modification of the atomic or molecular structure of the surface by physical or chemical methods.

Polymer structures offer several properties, such as biocompatibility, biodegradability and the option of functionalization, that render them suitable for the controlled pharmacokinetics of nanostructured active substances [27].

Examples of biological nanostructures are lipid-based nanotubes, nanospheres and emulsions. Best known are liposomes, which form a hollow sphere into whose lumen active ingredients can be introduced. A general toxicity of the enormously reactive nanoparticles has not been confirmed so far [28].
Carbon nanotubes and fullerenes have gained attention because they have a larger surface-to-volume-ratio and a smaller size. They form hollow, cage-like shapes and are very well suited for the transport of active ingredients.

In urology, kanamycin-chitosan nanoparticle coated stents showed enhanced antibacterial activity against *E. coli* and *P. mirabilis in vitro* [29]. Nano-structured scaffolds enhance urothelial repair function in injured rabbit bladders [30] and have been designed to replace the human urethra [31].

Currently, research aims at the optimization of the functionalization of implant surfaces by coating with signal molecules, such as growth factors, anti-inflammatory, or immunosuppressive substances with regards to integration and retention time.

**Antisense molecules**

Many pathogenic pathways depend on an insufficient or, to the contrary, excessive production of certain proteins [32]. More recently, antisense strategies were explored to address cancer, infectious diseases, chronic inflammatory diseases and metabolic conditions [33]. Antisense technology is a method that interferes with protein production. It can therefore be used in diseases in which the over- or underproduction of a specific protein play a crucial role. The principle is that an antisense nucleic acid sequence base pairs with its complementary sense RNA strand and prevents it from being translated into a protein [32] or interferes with its functional aspects [34]. Being a target-specific approach, it is highly attractive for treating underlying molecular disease pathways [33].

Antisense technology may be used to target urinary implant contamination, infection and biofilm formation. Biofilms contain various biological macromolecules, such as extracellular polysaccharides (EPS) and nucleic acids. This EPS matrix enhances the bacterial adhesion and promotes surface accumulation and cohesion resulting in extremely structured and adherent bacterial biofilms [35]. Consequently, bacteria in biofilms are 500 to 5000 times more resistant to antibiotics [36, 37]. Inhibition of EPS synthesis can prevent the formation of bacterial biofilms, reduce their robustness, and promote their removal [38]. Especially in early stages, this strategy allows the treatment of biofilm-mediated infection through early debridement and improved efficacy of antibiotics [39].

Research linking biofilm formation with environmental signal response systems in bacteria is still in its infancy. A greater understanding of the specific proteins which regulate formation
of single species (and multispecies) biofilms is needed [40]. Biofilms on urological stents and catheters are inherent and notorious. Inhibiting biofilm formation early would overcome many associated problems and antisense technology may open a door in the future.

**Tissue engineering**

Since the late 1980s, stents have been implanted to prevent scar contraction mainly in the urethra but also the ureter. Longer follow-up however relativized stenting as a primary treatment for stricture disease [41]. Permanent stents resulted in tissue in-growth and fibrosis complicating definite surgery. Temporary stents resulted in less tissue in-growth but still fibrosis. The ideal stent is flexible, supports regeneration, reduces fibrosis, and is biodegradable. In the urethra, it should support all functions of the penis in micturition and sexual activity in a flaccid and erect state. After degradation, it should be replaced by functional autologous tissue.

Not all urethral strictures can be treated by stenting. In hypospadias, extra urethral tissue is needed for reconstruction. Tissue engineering (TE) offers a possible solution to these challenges. TE for urethral reconstruction has been studied extensively [42, 43]. Yet, clinical trials have not proceeded beyond phase 2, and currently TE has not proceeded to clinical application. Major hurdles are tissue vascularization and tissue adaptation. In urethral strictures, frequently not only the urethral epithelium, but also the underlying fibrotic corpus spongiosum needs to be replaced [44, 45].

An attractive alternative might be *in vitro* TE of the ureter and urethra. In this approach, naturally derived (including autologous) and/or synthetic scaffolds [46, 47], will be seeded by different types of cells *in vitro*. Urethral or ureteric stents could act as such scaffolds or, in turn, such scaffolds could be formed as and act like stents until the tissue has been adopted. Various types of cells of different origin, including urine-derived stem cells [48] have already been tested in preclinical trials [49]. Grafts can then be transplanted to the recipients. However, insufficient graft vascularization often leads to rejection.

Theoretically, a “single step” transplantation following an extensive *in vitro* graft vascularization is possible. Combining acellular scaffolds with several vascularized cell sheets to generate *in vitro* ready-to-use grafts might open a great potential for ureteral and urethral TE [49, 50]. Stents and catheters can thus represent scaffolds to support the
engineered tissues, or could be covered with engineered tissue to be recognized by the recipient as "own".

**Encrustation sensing systems**

Bladder catheters and urinary stents share indications (urinary drainage), materials, and inherent problems (infection, encrustation, biofilms, blockages etc.). Research on either is therefore relevant to the other. With bladder catheters, blockage through encrustation is a frequent problem. It often results from urine infection with urease producing organisms, predominantly *Proteus mirabilis*. Urease generates ammonium which increases urinary pH, leading to struvite and apatite precipitation which form a crystalline biofilm that encrusts and blocks the urinary catheter. To reduce this problem, sensors have been incorporated in catheters to warn early of pH changes indicating impending blockage. To date, such pH sensors are mainly visual. A color strip indicated a risk of blockage 19 days before the actual blockage in early human trials [52]. Another indicator is a ‘trigger’ layer, usually EUDRAGIT®S 100, onto a hydrogel layer encapsulating a pH reporter or antibacterial agent. Upon elevation of urinary pH, the upper layer dissolves, triggering the release of a pH indicator such as carboxyfluorescein or bacteriophages. Both methods were tested in an *in vitro* bladder model. There was a 12h advanced warning of blockage, and a 13 to 26h advanced warning of delayed catheter blockage, respectively [53, 54]. Whereas catheters have an extracorporeal part that can carry those visual indicators, stents are entirely intracorporeal. However, in the age of nano-chip technology it seems entirely possible to fix a microsensor at one or both ends of a stent transmitting pH values or intrarenal pressure data indicating stent obstruction wirelessly.

**Biodegradable metal stents**

Biodegradable metals have a great potential for temporary ureteral stents due to their favourable mechanical properties that can overcome some of the limitations associated with biodegradable polymeric ureteral stents. Therefore, the use of metallic-based biodegradable ureteral stents is a novel and promising concept. 

Mg alloys were explored for their antibacterial properties (Mg-4%Yttrium (Mg-4Y), AZ31, and commercially pure Mg). There was a decrease in viable *E. coli* colonies after 3 days of culture in the presence of Mg alloys as compared to commercial polyurethane stents [55].
Pure Mg and ZK60 were studied for their *in vitro* corrosion in artificial urine (AU) and histocompatibility in rat bladders. ZK60 had a faster degradation both *in vitro* and in the rat bladders compared with pure Mg. Both metals revealed good biocompatibility during 3 weeks of implantation [56].

Another study explored the degradation of pure Zn, Zn-0.5Mg, Zn-1Mg, Zn 0.5% aluminium (Zn-0.5Al), pure Mg, and commercially available Mg-2Zn-1Mn in AU. Mg and its alloy had a faster degradation when compared with Zn. However, Zn alloys and Zn-0.5Al showed a more homogeneous corrosion which represents a valuable property for biodegradable ureteral stent [57]. In large animal model (*Guangxi Bama Minipig*) for ureteral stent application, a Mg based alloy (ZJ31) showed a homogeneous stent corrosion rate, a good biocompatibility with the animal’s urinary tract, and a higher antibacterial activity of ZJ31 when compared with stainless steel [58].

Even though biodegradable metal stenting in urology is a new concept and yet poorly explored, initial studies are promising.

**Bacteriophages**

Bacteriophages are viruses that enter bacteria, duplicate in them, and disrupt metabolic pathways of their hosts in the process. Bacteriophages destroy the bacterial cells and membranes (lytic), or duplicate in an intact bacterium (lysogenic) that then lives on.

Lytic viruses can be used as antimicrobial agents. They are effective and abundantly available.

Bacteriophages have a good antimicrobial selectivity and low cell toxicity. Therefore, they have recently kindled an interest as a component of medical device coatings [4].

In the lumen of bladder catheters pre-treated with the lytic *Staphyloccocus epidermidis* bacteriophage 456, a significant reduction of biofilm was shown [59].

Although bacteria can develop resistance to phages, a mixture of different lytic bacteriophages has been shown to be able to prevent this [60-62]. Silicone hydrogel coated bladder catheters pretreated with such phage cocktails showed significant antimicrobial activity. Therefore, mixed-species biofilms may be targeted by adapting the coating
composition and mixture of phages [63].

Although the above studies all have been using bladder catheter contamination and infection as a model, the use of bacteriophages targeting biofilms on urinary stents seems promising and feasible. Bacteriophages are highly effective antimicrobial agents; and they can be incorporated into coatings of medical devices. Most importantly, in an era of ever increasing bacterial resistance to antibiotic drugs, they may be a viable alternative avoiding just that [4].

**Non-pathogenic bacteria**

The beneficial effects of using non-pathogenic bacteria to manage biofilm infections can be attained by different mechanisms:

i) pathogen growth inhibition by antimicrobial substances and metabolites produced by the non-pathogen

ii) competitive exclusion of pathogens by blocking adhesion sites

iii) increased adhesion of the non-pathogen to the stent surface and subsequent inhibition of pathogen adhesion

iv) competition for nutrients

v) co-aggregation with the pathogen and

vi) modulation of the immune system.

Non-pathogenic bacteria can produce several antagonistic substances such as surfactants, bacteriocins, extracellular polymeric substances (EPS), organic acids, lactic acid, fatty acids, enzymes, and hydrogen peroxide [64], all of which can negatively affect the pathogens and/or decrease their adhesion to the stent surface. Additionally, using non-pathogenic bacteria as a live protective barrier against pathogen colonization may be advantageous because the anti-pathogen coating is self-renewable, potentially enabling a long-term activity [65].

It was shown that a probiotic *Escherichia coli* strain Nissle 1917 forms stable biofilms on silicone surfaces particularly after modification with a biphenyl mannoside derivative. These biofilms were able to reduce the colonization by pathogenic *Enterococcus faecalis* for 11 days [65]. In another study, a *Lactococcus lactis* strain was genetically modified to produce the FimH virulence factor of uropathogenic *Escherichia coli* (UPEC) on the cell surface. This
strain was able to form robust biofilms in abiotic surfaces and survived in the mice bladder. The protective effect against UPEC was demonstrated using a urinary tract infection (UTI) mouse model [66]. It has been shown in vivo and in vitro that Lactobacillus salivarius and its bacteriocin (salivaricin LHM) may be used as a therapeutic and prophylactic agent against Pseudomonas aeruginosa infections of the urinary tract [64]. Although these studies did not address the specific case of urological stents, the use of non-pathogenic bacteria to manage biofilm infection on these devices seems a promising strategy given the experimental conditions that were used.

**Preserving ureter peristalsis**

In physiological conditions, ureteral peristalsis ensures the movement of urine from the renal pelvis to the bladder in the form of boli. The insertion of an indwelling ureteral stent leads to an initial increase of peristaltic activity which is later reduced or stopped completely. Smaller stents were reported to have lower initial effects on the peristalsis. Irrespectively, eventually all types of stents do cause aperistalsis [67].

Despite the wide clinical application of ureteral stents, the mechanisms leading to a cessation of peristalsis are still poorly understood. There are few models [68] and studies reporting artificially triggered ureteral peristalsis:

- pharmacologically i.e. capsaicin
- mechanically i.e. applying distension
- electrical stimulation [69-71].

Peristalsis can be triggered by electrical stimulation in ex-vivo ureters with an indwelling catheter of a similar size like conventional ureteral stents. All ex-vivo ureters showed viability up to 3 hours [71].

Preserving ureteral peristalsis in stented ureters represents a potential innovative strategy against encrustation and biofilm formation on ureteral stents as it may have a ‘flushing’ effect on encrusted and biofilm deposits on the stent surface. In-vivo experiments would be needed to test the possibility of artificially preserving ureter peristalsis in the long term in stented ureters.
**Electrical charges to prevent biofilm adhesion**

Electrostatic attraction is one of the key factors influencing the initial interaction between bacteria and material surfaces. Most bacterial genera have a net negative charge and are therefore prone to attach to positively charged surfaces. Consequently, two types of engagement can be derived as antibacterial strategies, namely the material as a repellent or as a contact-killing agent.

The first strategy suggests materials with high negative charge densities to be deployed as anti-bacterial stent material or coating to prevent bacterial cells from contact. Heparin, having a strong negative charge density is a potent inhibitor of encrustations and is often incorporated as a coating material in commercially available ureteral stents. However, its effectiveness to prevent biofilm is still a matter of debate [72, 73].

In contrast, the contact-killing strategy relies on a positively charged surface and a permeabilization of the bacterial cell surface that leads to the leakage of intracellular material and eventual cell death. One of the reported approaches involves grafting polyethyleneimine (PEI) [74] micro-brushes onto polyurethane (PU) stents followed by an alkylation process [75, 76]. The resulting micro-structure of PEI brushes with positive charges showed a reduction in both biofilm and encrustation *in vitro* and *in vivo* [76].

Another contact-killing agent is chitosan, a biopolymer with antimicrobial properties through various modes of action [77, 78]. A freeze-casting process was proposed to make entire ureteral stents out of chitosan [79].

In addition, there is an increased susceptibility of biofilm cells to antibiotics in an electric field, the “bioelectric effect” [80].

Thus, electrical charges of the stent surface seem to play a crucial role in preventing bacterial adhesion and ensuing encrustation.

**Ultrasound waves to prevent bacterial adhesion on urological devices**

Antimicrobial treatments based on the use of mechanical stimuli have gained increasing attention in recent years, often as an alternative (or adjuvant) to antibiotics. The use of
ultrasound (US) energy is a clinically viable means to deliver mechanical stimulation within
the body. Ultrasound is sound waves (often in the form of longitudinal pressure waves) with
a frequency >20’000 Hz generated from a piezoceramic transducer. Previous studies have
demonstrated that US causes detachment of bacterial biofilms from material surfaces, as
well as enhances delivery of antibiotics into both planktonic cells and biofilms. The
mechanical action of ultrasound can be enhanced by the presence of gas microbubbles
which undergo oscillations upon exposure to ultrasound waves (a process known as
‘cavitation’). These bubbles form from gases dissolved in the fluid, or can be engineered for
a specific application [81]. Ultrasound waves can also be transmitted along a surface
(referred to as surface acoustic waves, or SAWs). It has been hypothesized that the resulting
surface vibrations prevent or delay bacterial adhesion [82]. The latter approach has been
employed against biofilm formation in urological catheters, and is realized by coupling the
extra-corporeal segment of the catheter with piezoceramic elements, generating SAWs in
the frequency range 100-300 kHz. It has been estimated that surface oscillations can
propagate over the entire surfaces of a catheter with an amplitude of 0.2-2 nm. The
effectiveness of this method in preventing biofilm development on Foley bladder catheters,
both in-vitro and in a rabbit model has been evaluated. SAW-activated catheters presented
a marked reduction in biofilm load in-vitro, irrespective of the bacterial strain, which was
attributed to SAW-induced inhibition of bacterial surface adhesion. This effect was more
prominent with lower SAW intensities (0.05-0.20 mW/cm²). These observations were
corroborated through studies in-vivo where the average number of days to development of
urinary tract infection was 7.3±1.3 days (SAW-catheter group) as opposed to 1.5±0.6 days
(non-treated group) [83].

Notably, a commercial SAW-activated catheter (UroShield™) has been developed by
NanoVibronix Inc. (USA). In 2008, Zillich et al. reported on the outcome of a randomized
double blinded clinical study on 22 patients, evaluating efficacy and safety of UroShield™.
Catheters were deployed for an average of ~9 days, and it was concluded that patients with
UroShield™ presented with lower pain and spasm levels, as well as a marked reduction in
the level of biofilm formation [84]. A more recent study reported on a double blinded
randomized control trial involving 55 patients, who had an indwelling urinary or suprapubic
catheter for >1-year and had a treated UTI in the 90 days before the study. Patients were
inserted UroShield™ (or a control catheter) for 30 days. Overall, the SAW-activated UroShield™ was able to significantly reduce the bacterial load in the large majority of subjects [85].

Despite these studies demonstrating that ultrasonic SAWs can effectively prevent or delay bacterial adhesion on urological devices, to the best of the authors’ knowledge this approach has not yet been tried in urological stents. The development of such a SAW-activated stent will require evaluation of technological aspects associated with the coupling and powering of the SAW source, differences in the material properties of commercial stents, and the effect of geometrical features of the stent on SAW propagation (i.e. such as side-holes and double-J ends).

**Conclusions**

The ENIUS network provided a unique opportunity for a multidisciplinary scientific exchange. However, it became also abundantly clear that on one hand many researchers work in isolation, on a specific aspect of urological implant development and without being aware of cross-research projects or clinical implications. On the other hand, clinicians who use urinary implants daily are often not aware of the amount of research that has gone into the development of these little pieces of metal and plastic. Addressing various aspects of research and development in the field was truly an eye opener for all stakeholders. Therefore, this paper hopefully will enable them to consider various research approaches for the same problems and open way for collaboration and cross-thinking.

Up to date, most of urological implant research was focusing on structural and material improvements (which is still ongoing) but it is fascinating to see the shift towards cellular, molecular and micro-environmental approaches, the latter encompassing external proteins, antibodies, enzymes, competing bacteria and viruses.

All approaches listed in this paper seem viable and promising. Some of them have been around for decades but have not proceeded to clinical application (i.e. tissue engineering) and others are very recent and, at least in urology, still only conceptual (i.e. antisense molecules).

Perhaps the most important conclusion resulting from this pan-European multidisciplinary effort is that collaboration between all stakeholders is not only fruitful but essential.
Funding

ENIUS (CA16217) is supported by the European Cooperation in Science and Technology (COST). It is a four-year project (COST action). COST is a funding organization by the European Union (EU) for the creation of research networks.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

All authors have contributed to the conceptualization, referencing, content, writing, editing and proof reading of this manuscript.
References

9. www.enius.org (last accessed 18th March 2021)


